Chief Scientific Officer

1.    The Position

  • The CSO for Tilos will be the scientific face of the company and effectively lead, create, and communicate key strategies
  • The position is based in Cambridge, Massachusetts
  • The CSO will report directly to Barbara Fox, CEO of Tilos

2.    Core Responsibilities

  • The CSO will lead research, translational and preclinical development from target selection through early drug discovery and to IND, as well as all pipeline development efforts.
  • Responsible for establishing company’s strategic R&D roadmap and to provide exemplary scientific input into company’s research and development programs in order to support the overall corporate strategy set by the Board. 
  • This individual must have strong communication skills in order to articulate this strategy to employees, Board members, investors and external partners.
  • This individual must also be highly skilled in working with external partners. Tilos will likely have considerable involvement with the discovery and development groups within leading pharmaceutical partner companies. As a result of these collaborations, the individual must have presence, credibility and a style that bodes well for success in such relationships. 
  • Responsible for providing strategic input for company’s mid- and long-term scientific and corporate development goals.
  • Serve as chair of the Scientific Advisory Board and be responsible for the composition, relationship development, and value adding output from company’s SAB.
  • Specific responsibilities in directing the discovery, preclinical and translational science programs:
  1. To provide overall scientific operational leadership in identifying, evaluating and developing novel preclinical drug development opportunities and candidates and progressing them into IND-enabling studies and into human PoC clinical trials.
  2. To advance the company’s scientific and translational science leadership
  3. Seeking partnerships with academic institutions, with pharmaceutical companies and with other strategic partners.
  4. Managing the company’s patent estate. 
  5. Making formal presentations at medical, scientific, strategic partnering and fundraising meetings on behalf of the Company

3.    Scientific

  • Lead cutting edge research and drug development with the primary focus in the area of Immuno-oncology.  Experience in the areas of fibrosis and autoimmunity would also be of value. 
  • Lead key activities resulting in the selection of preclinical drug development candidates for the company to pursue.
  • Lead and manage the overall preclinical activities of Tilos’ product candidates through IND-enabling studies, including discovery, biology, pharmacology, biomarker strategy, and safety assessment.

4.    Strategy

  • Provide visionary, passionate and inspiring scientific leadership, both internally and externally when aligning scientific expectations with the corporate vision.
  • Play the lead role in defining and executing on the R&D strategy, which includes being able to clearly articulate how Tilos’ products would be clinically differentiated, identifying opportunities and threats; and evaluating options and plans that take into consideration both scientific and commercial factors.

5.    Managerial/Business

  • Providing leadership in managing Tilos’ research and preclinical development projects and teams and ensuring that they remain within budget, scope and schedule requirements.
  • Lead the hiring of world-class team members to support the development of the lead program and the pipeline
  • Oversee scientific operations.
  • Implement scientific decision-making processes to assess and develop multiple pipeline candidates with clear go/no-go staged project investment decisions.
  • Providing tracking and analysis of project expenditures and resource requirements, as necessary, in order to stay within budget.
  • Identifying and negotiating outsourced and/or collaborative arrangements with partners.

6.    The Individual

  • We are seeking either a PhD or an MD/PhD with a preferred emphasis on immunology and oncology. 
  • We are seeking an individual with a minimum of fifteen years of experience working in a complex, scientific environment, half of which should have come in a managerial context. The time spent in a corporate setting must be both significant and have been proven impactful. Therefore, it is essential for the individual to have come from an environment in which biologics have been moved out of basic research, through preclinical evaluation and into the clinic. 
  • Above and beyond all else, this individual must be a prominent and proven scientist, preferably with a deep understanding of antibody-based oncology therapy, who is capable of working on both high level strategy and in managing and mentoring others within this growing company. 
  • From the perspective of preferred functional strengths, we expect this executive to have demonstrated competency in basic research, antibody technology, target identification, biomarker and drug product selection, as well as preclinical expertise (e.g., experience with a range of immune-oncology pharmacology models).
  • We are looking for an individual with a successful track record in the biopharmaceutical industry. The CSO must have significant credibility and scientific credentials, be viewed as a viable industry figure of consequence and have a demonstrated track record of successfully advancing drug candidates through proof of concept and into the market. 


Interested candidates should submit a cover letter and CV to Barbara S. Fox, CEO, at